Oncopeptides, a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has appointed Jakob Lindberg as CEO of Oncopeptides. Effective immediately, Lindberg replaces Marty J Duvall, who has been CEO since July 1, 2020. The leadership change follows the withdrawal of Pepaxto (INN melphalan flufenamide) from the US market and the…
Home Healthcare Markets International People Sweden: Lindberg replaces Duvall as CEO at Oncopeptides following withdrawal of Pepaxto...